Search results for "type"

showing 10 items of 10618 documents

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

2013

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 …

medicine.medical_specialtyLipoproteinsIncretin type 2 diabetes mellitus metabolic syndrome lipoproteinsIncretinBiologyIncretinsGlucagon-Like Peptide-1 ReceptorWeight lossDiabetes mellitusInternal medicineDrug DiscoverymedicineAnimalsHumansGlucose homeostasisAdiponectin secretionLipoproteinInflammationPharmacologyDipeptidyl-Peptidase IV InhibitorsDrug Discovery3003 Pharmaceutical ScienceMedicine (all)digestive oral and skin physiologyGlucagon secretionType 2 Diabetes MellitusIncretinAtherosclerosismedicine.diseaseMetabolic syndromeType 2 diabetes mellituGlucoseEndocrinologyDiabetes Mellitus Type 2Metabolic syndromemedicine.symptomCurrent Pharmaceutical Design
researchProduct

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.

2004

Type 2 diabetes is an important cardiovascular risk factor. A significant component of the risk associated with type 2 diabetes is thought to be because of its characteristic lipid "triad" profile of raised small dense low-density lipoprotein levels, lowered high-density lipoprotein, and elevated triglycerides (TGs). Trials of statins and fibrates have included substantial numbers of patients with diabetes and indicate that lipid lowering reduces cardiovascular event rates in these patients. However, statins alone do not always address all the lipid abnormalities of diabetes. Fibrates, which have low affinity for peroxisome proliferator-activated receptor alpha (PPARalpha), improve most asp…

medicine.medical_specialtyLipoproteinsPeroxisome proliferator-activated receptorType 2 diabetesInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineLipolysisHumansPPAR alphaDyslipidemiaschemistry.chemical_classificationbusiness.industrynutritional and metabolic diseasesLipid metabolismmedicine.diseaseLipid MetabolismEndocrinologychemistryDiabetes Mellitus Type 2Cardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAmerican heart journal
researchProduct

Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

2019

Abstract Background Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need. Structure The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a …

medicine.medical_specialtyLithium (medication)[SDV]Life Sciences [q-bio]Psychological interventionOmicsNeuroimagingReviewLithiumDigitallcsh:RC321-57103 medical and health sciences0302 clinical medicinemedicineProspective cohort studyIntensive care medicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryPersonalizationbusiness.industrylcsh:QP351-495ResponseActigraphyPrecisionOmicsActigraphy3. Good health030227 psychiatryPsychiatry and Mental healthlcsh:Neurophysiology and neuropsychologyPhenotypeMoodTolerabilityBipolarBiomarker (medicine)business030217 neurology & neurosurgerymedicine.drugInternational Journal of Bipolar Disorders
researchProduct

Positive Airway Pressure Treatment Reduces Glycated Hemoglobin (HbA1c) Levels in Obstructive Sleep Apnea Patients: Longitudinal Data from the Esada

2019

European-Respiratory-Society (ERS) International Congress -- SEP 28-OCT 02, 2019 -- Madrid, SPAIN

medicine.medical_specialtyLongitudinal dataGastroenterologyComorbidities03 medical and health sciencesHba1c levelchemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinePositive airway pressuremedicine030212 general & internal medicinebusiness.industryType 2 Diabetes MellitusSleep apneaSystemic effectmedicine.diseaserespiratory tract diseasesObstructive sleep apnea030228 respiratory systemApnea–hypopnea indexchemistryCardiologyGlycated hemoglobinbusinessBody mass indexTurkish Thoracic Journal
researchProduct

Periodontal disease and diabetes : review of the literature

2010

Aims: To provide updated knowledge on the relationship between periodontal disease and diabetes from an oral health perspective. Methods: A review of the English-language literature was performed, gathering articles on the two diseases published over the past 10 years. Results: Both diseases result from the confluence of various triggering and modifying factors, and there are inter-individual differences in the risk of their development. Recent research has shown that diabetes may increase the risk of periodontitis, and it has been proposed that chronic periodontal disease may influence the natural course of diabetes. There appears to be an association among oral infections, impaired sugar …

medicine.medical_specialtyMEDLINEDentistryType 2 diabetesDiabetes Complications03 medical and health sciences0302 clinical medicinePeriodontal diseaseDiabetes mellitusmedicineHumans030212 general & internal medicineIntensive care medicineGeneral DentistryPeriodontal DiseasesGlycemicPeriodontitisNatural coursebusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]3. Good healthDiabetes Mellitus Type 2OtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryMetabolic syndromebusiness
researchProduct

Oral health effects of botulinum toxin treatment for drooling:a systematic review

2020

Background Drooling is a major morbidity in several neurological diseases. Intraglandular botulinum neurotoxin (BoNT) injections have been used to manage this condition. However, by decreasing salivary flow, BoNT injections may result in an increased risk of caries and other oral adverse effects. In this study, we aimed to assess whether, in patients with drooling, intraglandular BoNT injections are associated with increased dental caries development, modifications on salivary composition (oral pH, buffering capacity and osmolality) and cariogenic bacterial load. Material and Methods We performed a systematic review, searching PubMed, CENTRAL, Web of Science, and Scopus for all experimental…

medicine.medical_specialtyMEDLINEOral HealthReviewOral healthDental CariesDroolinglaw.inventionameloblastomaRandomized controlled triallawInternal medicinemedicineHumansBotulinum Toxins Type AAdverse effectGeneral DentistryUNESCO:CIENCIAS MÉDICASbusiness.industryCerebral Palsyodontogenic tumorSialorrheaMedically compromised patients in Dentistryameloblastoma recurrenceBotulinum toxinOtorhinolaryngologyNeuromuscular AgentsSurgeryObservational studymedicine.symptombusinessoral pathologyBiomedical sciencesmedicine.drug
researchProduct

Magnesium metabolism in hypertension and type 2 diabetes mellitus.

2007

The increasing evidence for the clinical relevance of altered magnesium metabolism to states of altered insulin resistance confirms the role of magnesium deficit as a possible underlying common mechanism of the "insulin resistance" of hypertension and altered glucose tolerance. The pioneer work of Lawrence M. Resnick and his group using the cellular ion-based approach that we are only partially presenting here has consistently contributed to the progress of the field, demonstrating (a) the critical importance of magnesium metabolism in regulating insulin sensitivity as well as vascular tone, and blood-pressure homeostasis; (b) that magnesium deficiency, defined on the basis of intracellular…

medicine.medical_specialtyMagnetic Resonance Spectroscopychemistry.chemical_elementEssential hypertensionInsulin resistancePre-EclampsiaPregnancyMagnesium deficiency (medicine)Diabetes mellitusInternal medicinemedicineHumansPharmacology (medical)MagnesiumSodium Chloride DietaryPharmacologyCalcium metabolismMagnesiumbusiness.industryType 2 Diabetes MellitusGeneral MedicineSyndromemedicine.diseaseEndocrinologychemistryDiabetes Mellitus Type 2HypertensionCalciumFemaleInsulin ResistancebusinessMagnesium DeficiencyHomeostasisAmerican journal of therapeutics
researchProduct

Weaning induces NOS-2 expression through NF-κB modulation in the lactating mammary gland: importance of GSH

2005

Zaragozá, R; Miralles, VJ; Rus, AD; García, C; Carmena, R; García-Trevijano, ER; Barber, T; Pallardó, FV; Torres, L; Viña, JR. At the end of lactation the mammary gland undergoes involution, a process characterized by apoptosis of secretory cells and tissue remodelling. To gain insight into this process, we analysed the gene expression profile by oligonucleotide microarrays during lactation and after forced weaning. Up-regulation of inflammatory mediators and acute-phase response genes during weaning was found. Expression of IκBα (inhibitory κBα), a protein known to modulate NF-κB (nuclear factor-κB) nuclear translocation, was significantly up-regulated. On the other hand, there was a time-…

medicine.medical_specialtyMammary glandDown-RegulationNitric Oxide Synthase Type IIWeaninglactationBiologyBiochemistryNF-κBMammary Glands AnimalWestern blotnitric oxideInternal medicineLactationGene expressionmedicineGSHinvolutionWeaningAnimalsInvolution (medicine)Rats WistarPromoter Regions GeneticMolecular Biologymedicine.diagnostic_test:CIENCIAS DE LA VIDA::Bioquímica [UNESCO]Gene Expression ProfilingNF-kappa BUNESCO::CIENCIAS DE LA VIDA::BioquímicaCell BiologyGlutathioneRatsUp-RegulationIκBαProtein Transportmedicine.anatomical_structureEndocrinologyEnzyme InductionFemaleChromatin immunoprecipitationProtein BindingResearch Article
researchProduct

Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease

2020

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A r…

medicine.medical_specialtyMedicina030232 urology & nephrologyRenal functionReviewsType 2 diabetes030204 cardiovascular system & hematologyDiabetic nephropathy03 medical and health sciences0302 clinical medicineSodium-Glucose Transporter 2Internal medicineDiabetes mellitusDiabetic nephropathiesmedicineChronic renal failureHumansDiabetic NephropathiesDiabetic kidney diseaseESRDSodium-Glucose Transporter 2 InhibitorsTransplantationbusiness.industryType 2 diabetesNefropaties diabètiquesmedicine.diseasePrognosisBlood pressureDiabetes Mellitus Type 2NephrologyHeart failureSodium/Glucose Cotransporter 2Insuficiència renal crònicabusinessSGLT2 inhibitorsKidney disease
researchProduct

GLP-1 Receptor agonists and diabetic kidney disease: A call of attention to nephrologists

2020

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 r…

medicine.medical_specialtyMedicinaRenal functionlcsh:Medicine030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyHypoglycemiaurologic and male genital diseases03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineChronic kidney diseaseMedicineMalalties cròniquesDiabetic kidney diseaseGlycemicKidneyProteinuriaKidney diseasesbusiness.industrylcsh:RType 2 Diabetes MellitusGeneral Medicinemedicine.diseasediabetic kidney diseasemedicine.anatomical_structureChronic diseasesMalalties del ronyómedicine.symptombusinessGLP-1chronic kidney diseaseKidney disease
researchProduct